Your browser doesn't support javascript.
loading
Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.
Karacin, Cengiz; Eren, Tulay; Zeynelgil, Esra; Imamoglu, Goksen Inanc; Altinbas, Mustafa; Karadag, Ibrahim; Basal, Fatma Bugdayci; Bilgetekin, Irem; Sutcuoglu, Osman; Yazici, Ozan; Ozdemir, Nuriye; Ozet, Ahmet; Yildiz, Yesim; Esen, Selin Akturk; Ucar, Gokhan; Uncu, Dogan; Dinc, Bedia; Aykan, Musa Baris; Erturk, Ismail; Karadurmus, Nuri; Civelek, Burak; Çelik, Ismail; Ergun, Yakup; Dogan, Mutlu; Oksuzoglu, Omur Berna.
Afiliação
  • Karacin C; Department of Medical Oncology, Recep Tayyip Erdogan University Training & Research Hospital, Rize, Turkey.
  • Eren T; Department of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training & Research Hospital, Ankara, Turkey.
  • Zeynelgil E; Department of Medical Oncology, HSU Diskapi Yildirim Beyazit Training & Research Hospital, Ankara, Turkey.
  • Imamoglu GI; Department of Medical Oncology, HSU Diskapi Yildirim Beyazit Training & Research Hospital, Ankara, Turkey.
  • Altinbas M; Department of Medical Oncology, HSU Diskapi Yildirim Beyazit Training & Research Hospital, Ankara, Turkey.
  • Karadag I; Department of Medical Oncology, HSU Diskapi Yildirim Beyazit Training & Research Hospital, Ankara, Turkey.
  • Basal FB; Department of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training & Research Hospital, Ankara, Turkey.
  • Bilgetekin I; Department of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training & Research Hospital, Ankara, Turkey.
  • Sutcuoglu O; Department of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training & Research Hospital, Ankara, Turkey.
  • Yazici O; Department of Medical Oncology, Gazi University, Ankara, Turkey.
  • Ozdemir N; Department of Medical Oncology, Gazi University, Ankara, Turkey.
  • Ozet A; Department of Medical Oncology, Gazi University, Ankara, Turkey.
  • Yildiz Y; Department of Medical Oncology, Gazi University, Ankara, Turkey.
  • Esen SA; Department of Infectious Diseases & Clinical Microbiology, Gazi University, Ankara, Turkey.
  • Ucar G; Department of Medical Oncology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
  • Uncu D; Department of Medical Oncology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
  • Dinc B; Department of Medical Oncology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
  • Aykan MB; Department of Medical Microbiology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
  • Erturk I; Department of Medical Oncology, HSU Gulhane Training & Research Hospital, Ankara, Turkey.
  • Karadurmus N; Department of Medical Oncology, HSU Gulhane Training & Research Hospital, Ankara, Turkey.
  • Civelek B; Department of Medical Oncology, HSU Gulhane Training & Research Hospital, Ankara, Turkey.
  • Çelik I; Department of Medical Oncology, A Life Hospital, Ankara, Turkey.
  • Ergun Y; Department of Preventive Oncology, Institute of Oncology, Hacettepe University, Ankara, Turkey.
  • Dogan M; Department of Medical Oncology, Batman Training & Research Hospital, Batman, Turkey.
  • Oksuzoglu OB; Department of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training & Research Hospital, Ankara, Turkey.
Future Oncol ; 17(33): 4447-4456, 2021 Nov.
Article em En | MEDLINE | ID: mdl-34342517
ABSTRACT

Aim:

To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.

Methods:

This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 µg/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as 'immunogenicity.'

Results:

The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio 0.830; p = 0.043).

Conclusion:

More than half of cancer patients receiving active systemic therapy developed immunogenicity.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Future Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Future Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia